Mereo BioPharma Group (HAM:MAH0) EV-to-Revenue : 53.59 (As of Jun. 23, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Mereo BioPharma Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Mereo BioPharma Group's enterprise value is €494.36 Mil. Mereo BioPharma Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €9.22 Mil. Therefore, Mereo BioPharma Group's EV-to-Revenue for today is 53.59.

The historical rank and industry rank for Mereo BioPharma Group's EV-to-Revenue or its related term are showing as below:

HAM:MAH0' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.36 Med: 0.75 Max: 51.3
Current: 56.55

During the past 9 years, the highest EV-to-Revenue of Mereo BioPharma Group was 51.30. The lowest was -1.36. And the median was 0.75.

HAM:MAH0's EV-to-Revenue is ranked worse than
78.92% of 1034 companies
in the Biotechnology industry
Industry Median: 7.69 vs HAM:MAH0: 56.55

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-23), Mereo BioPharma Group's stock price is €3.55. Mereo BioPharma Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.07. Therefore, Mereo BioPharma Group's PS Ratio for today is 48.63.

Mereo BioPharma Group EV-to-Revenue Historical Data

The historical data trend for Mereo BioPharma Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group EV-to-Revenue Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

1.72

27.91

Mereo BioPharma Group Quarterly Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial												1.72	-	-	-	27.91

Competitive Comparison of Mereo BioPharma Group's EV-to-Revenue

For the Biotechnology subindustry, Mereo BioPharma Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mereo BioPharma Group's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's EV-to-Revenue falls into.

Mereo BioPharma Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Mereo BioPharma Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	494.360	/	9.224
	=	53.59

Mereo BioPharma Group's current Enterprise Value is €494.36 Mil.
Mereo BioPharma Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.22 Mil.

Mereo BioPharma Group (HAM:MAH0) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Mereo BioPharma Group's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	3.55	/	0.073
	=	48.63

Mereo BioPharma Group's share price for today is €3.55.
Mereo BioPharma Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.07.

Mereo BioPharma Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group (HAM:MAH0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (HAM:MAH0) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

MREO:USA 0A9G:UK MAH0:Germany MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.

Mereo BioPharma Group (HAM:MAH0) Headlines

No Headlines